Holen Sie sich die Stockscreener-App
12.46
0.81%
0.10
Vorhandelsmarkt:
12.41
-0.05
-0.40%
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Wedbush Maintains Cullinan Therapeutics (CGEM) Outperform Recommendation - Nasdaq
Cullinan Therapeutics shows rising price performance with jump to 93 RS rating - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 - MarketBeat
Wedbush Raises Price Target on CGEM to $34, Maintains Outperform - GuruFocus
CGEM: CLN-049 demonstrates strong efficacy and safety in AML, advancing toward pivotal trials - TradingView
Cullinan Therapeutics (NASDAQ:CGEM) Trading 9.3% HigherWhat's Next? - MarketBeat
Cullinan Oncology stock soars after promising AML treatment results By Investing.com - Investing.com Canada
Cullinan’s leukemia drug shows promising results in clinical trial By Investing.com - Investing.com South Africa
Cullinan Therapeutics Presents Promising CLN-049 Data - TipRanks
Cullinan Therapeutics (CGEM) Reveals Encouraging Phase 1 Data fo - GuruFocus
Cullinan Therapeutics Showcases Compelling Clinical Data in - GlobeNewswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Investment Review: Will Cullinan Therapeutics Inc stock deliver better than expected guidance2025 Dividend Review & Breakout Confirmation Alerts - BỘ NỘI VỤ
Why Cullinan Therapeutics Inc. stock could benefit from AI revolution2025 Volatility Report & Weekly Hot Stock Watchlists - Newser
How Cullinan Therapeutics Inc. stock benefits from strong dollarJuly 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%What's Next? - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - Setenews
How Cullinan Therapeutics Inc. stock responds to policy changesEarnings Risk Summary & Free Weekly Watchlist of Top Performers - Newser
FDA grants fast track designation to Cullinan’s AML therapy By Investing.com - Investing.com Australia
Cullinan Oncology stock rises after FDA Fast Track designation for leukemia drug - Investing.com Canada
Cullinan Therapeutics receives FDA fast track designation for CLN-049 - marketscreener.com
CGEM Receives FDA Fast Track for CLN-049 in Leukemia Treatment - GuruFocus
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - The Manila Times
Cullinan Therapeutics' CLN-049 Receives FDA Fast Track Designation for Treatment of Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
FDA grants fast track designation to Cullinan’s AML therapy - Investing.com
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells 4,000 Shares of Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 7.6%Should You Sell? - MarketBeat
Cullinan Oncology stock price target raised to $36 at Jones Trading - Investing.com Nigeria
Why Cullinan Therapeutics (CGEM) Is Up 38.1% After FDA Filing for EGFR-mutant Lung Cancer Drug - Sahm
Buy Rating for Cullinan Therapeutics Driven by Promising AML Treatment Developments and Strong Market Potential - TipRanks
Foresite Capital Management VI LLC Lowers Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer (PR Newswire) - Aktiellt
Cullinan Therapeutics (NASDAQ:CGEM) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Investors Purchase High Volume of Call Options on Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
Is Cullinan Therapeutics Inc (CGEM) positioned for future growth? - Setenews
Cullinan Oncology stock price target raised to $38 at BTIG on promising AML data - Investing.com Canada
Taiho, Cullinan file rolling NDA on phase I/II zipalertinib data - BioWorld MedTech
BTIG Maintains Cullinan Therapeutics (CGEM) Buy Recommendation - Nasdaq
Cullinan Therapeutics (CGEM) Receives PT Upgrade from BTIG Analy - GuruFocus
Cullinan Therapeutics price target raised to $38 from $32 at BTIG - TipRanks
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Cullinan Management Ends Development of CLN-617 - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $26.00 - Defense World
Wall Street Zen Upgrades Cullinan Therapeutics (NASDAQ:CGEM) to Hold - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Wedbush Reiterates “Outperform” Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics' (CGEM) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Cullinan TherapeuticsCullinan Amber notified MIT decision to terminate exclusive patent license agreement for CLN-617 - marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 8.5% Following Analyst Upgrade - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 8.5% After Analyst Upgrade - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Otsuka units file for US approval for zipalertinib - The Pharma Letter
Cullinan Therapeutics (CGEM) Advances with FDA Acceptance for Lu - GuruFocus
Cullinan Therapeutics rises on rolling submission for zipalertinib - MSN
HC Wainwright & Co. Maintains Cullinan Therapeutics (CGEM) Buy Recommendation - Nasdaq
HC Wainwright & Co. Raises Price Target for CGEM to $26.00 | CGE - GuruFocus
CGEM Advances NDA for Zipalertinib Targeting EGFR Mutations in N - GuruFocus
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics initiate rolling submission of new drug application to US FDA - MarketScreener
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):